share_log

Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies

Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies

Twist Bioscience與Astellas聯手開發抗癌靶向抗體
Benzinga Real-time News ·  2022/05/09 13:58
  • Twist Bioscience Corporation (NASDAQ:TWST) has entered into a research collaboration and exclusive option license agreement with Astellas Pharma Inc (OTC:ALPMF) to conduct research activities to identify and optimize proprietary Twist antagonist antibodies.
  • The antibodies will target an undisclosed checkpoint inhibitor pathway in the tumor microenvironment as potential therapeutic development candidates. 
  • Ligands in this pathway are found in relatively high concentrations in the tumor microenvironment. 
  • Also Read: Twist Bioscience Inks Antibody Discovery Pact With MediSix Therapeutics.
  • Blocking the receptor's activation can markedly enhance anti-tumor immunity with other Astellas therapies, including chimeric antigen receptor-based technologies combined with Universal Donor Cells. 
  • Astellas will have the exclusive option to license any development candidates generated as part of the collaboration.
  • Under the terms of the agreement, Twist will receive an upfront payment from Astellas and an additional payment upon the exercise of the licensing option. 
  • Twist will receive payments connected to success-based clinical milestones and sales-based royalty payments for each licensed product. 
  • Specific deal terms were not disclosed.
  • Astellas will be responsible for developing, manufacturing, and commercializing any licensed products.
  • Price Action: TWST shares are down 11.2% at $27.87 during the market session on the last check Monday.
  • 特威斯特生物科學公司納斯達克(股票代碼：TWST)已與以下公司簽訂研究合作和獨家選項許可協議阿斯特拉斯製藥公司(場外交易代碼：ALPMF)開展研究活動，以識別和優化專利的Twist拮抗劑抗體。
  • 這些抗體將靶向腫瘤微環境中一個未披露的檢查點抑制因子途徑，作為潛在的治療開發候選。
  • 該途徑中的配體在腫瘤微環境中的濃度相對較高。
  • 另請閲讀： Twist Bioscience墨水公司與MediSix Treateutics簽署抗體發現協議.
  • 阻斷受體的激活可以顯著增強其他Astellas療法的抗腫瘤免疫能力，包括基於嵌合抗原受體的技術與通用供體細胞相結合。
  • 作為合作的一部分，Astellas將擁有獨家許可任何開發候選者的選擇權。
  • 根據協議條款，Twist將從Astellas獲得預付款，並在行使許可選擇權時獲得額外付款。
  • Twist將獲得與基於成功的臨牀里程碑相關的付款，以及每個授權產品的基於銷售的版税付款。
  • 具體的交易條款沒有披露。
  • Astellas將負責任何許可產品的開發、製造和商業化。
  • 價格行動：在週一尾盤交易中，TWST股價下跌11.2%，至27.87美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論